Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial.
Adrian F HernandezJacob A UdellW Schuyler JonesStefan D AnkerMark Colquhoun PetrieJosephine HarringtonMichaela MattheusSvenja SeideIsabella ZwienerOffer AmirMaria Cecilia BahitJohann BauersachsAntoni Bayés-GenísYun-Dai ChenVijay K ChopraGemma A FigtreeJunbo GeShaun G GoodmanNina GotchevaShinya GotoTomasz GasiorWaheed JamalJames L JanuzziMyung Ho JeongYuri LopatinRenato Deláscio LopesBela MerkelyPuja B ParikhAlexander ParkhomenkoPiotr PonikowskiXavier RosselloMorten SchouDragan SimicPhillippe Gabriel StegJoanna SzachniewiczPeter Van der MeerDragos VinereanuShelley ZierothMartina BrueckmannMikhail SuminDeepak L BhattJaved ButlerPublished in: Circulation (2024)
In patients after acute myocardial infarction with left ventricular dysfunction or congestion, empagliflozin reduced the risk of heart failure.
Keyphrases
- acute myocardial infarction
- left ventricular
- heart failure
- cardiac resynchronization therapy
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- mitral valve
- clinical trial
- aortic stenosis
- prognostic factors
- study protocol
- randomized controlled trial
- oxidative stress
- atrial fibrillation
- phase ii
- chronic kidney disease
- open label